Melinta Therapeutics Presenting In Vivo and In Vitro Results from Baxdela Studies at ASM Microbe

Bactericidal Data on a Novel Pyrrolocytosine for Gonorrhea also presented

Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that five presentations of clinical, in vitro and pharmacokinetic results from studies of Baxdela™ (delafloxacin), an investigational anionic fluoroquinolone, will be presented at the ASM Microbe 2017 meeting.  In addition there will be an oral presentation on the potential of RX-P2177, a novel pyrrolocytosine antibiotic developed internally as part of our ESKAPE pathogen program that uses our proprietary ribosome-targeting platform.  RX-P2177 shows promising activity for the treatment of gonorrhea; details will be shared during a symposium on antimicrobial pharmacokinetics and pharmacodynamics.  ASM Microbe 2017 will take place June 1–5, 2017 in New Orleans, LA.